Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 11Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 7Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Solid Tumor 4Rectal Neoplasms 4Neoplasms 3Lymphoma 3Esophageal Neoplasms 3Colorectal Neoplasms 3Uterine Cervical Neoplasms 2Tongue Neoplasms 2Salivary Gland Neoplasms 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Breast Neoplasms, Male 2Thromboembolism 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma, Testicular 1Teratoma 1Spinal Cord Neoplasms 1Seminoma 1

Interventions

Cyclophosphamide 15fludarabine phosphate 14Peripheral Blood Stem Cell Transplantation 12Cyclosporine 12Filgrastim 10Whole-Body Irradiation 9Mycophenolic Acid 9Busulfan 7Antilymphocyte Serum 7Melphalan 5fludarabine 4Radiotherapy 4Psychiatric Rehabilitation 4Methylprednisolone 4Methotrexate 4Etoposide 4Cord Blood Stem Cell Transplantation 4Therapeutics 3Rituximab 3Granulocyte Colony-Stimulating Factor 3Aprepitant 3Analgesia 3plerixafor 2Tacrolimus 2Ondansetron 2Magnetic Resonance Spectroscopy 2Flow Cytometry 2Dexamethasone 2Carmustine 2Calcium Dobesilate 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Lymphoma, Mantle-Cell × Fluorodeoxyglucose F18 × Clear all
NCT00110006 2010-06-11

Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma

Case Comprehensive Cancer Center

Phase NA Withdrawn
Lymphoid

Lymphoma, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡